Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,409 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07028125 | Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma(CANIQOL) | recruiting | Phase 4 | 83 | Centre Francois BaclesseOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 |
| clinicaltrials |
| NCT06764095 | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial | recruiting | Phase 4 | 75 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06934057 | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma(CABOLD) | recruiting | Phase 4 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06903312 | Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.(ITALIC-RCC) | recruiting | Phase 4 | 409 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05805436 | Preop Laxatives in Robotic Urologic Surgery | recruiting | Phase 4 | 240 | Chad R. TracyOTHER | 1 | May 30, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jul 14, 2026source: clinicaltrials